Phase I/II Study of AZD2281 given in combination with paclitaxel in metastatic Triple Negative Breast Cancer

Study identifier:D0810C00011

ClinicalTrials.gov identifier:NCT00707707

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase I/II randomised, double- blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer.

Medical condition

Breast Cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD2281, Paclitaxel

Sex

Female

Actual Enrollment

19

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 15 Sept 2008
Primary Completion Date: 09 Nov 2009
Study Completion Date: 19 Feb 2018

Study design

Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2018 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria